Trial Profile
Phase 1/2, Open-label Study of Bosutinib Administered in Combination With Capecitabine in Subjects With Solid Tumor and ErbB2 Negative Locally Advanced or Metastatic Breast Cancer.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 24 Dec 2021
Price :
$35
*
At a glance
- Drugs Bosutinib (Primary) ; Capecitabine (Primary)
- Indications Advanced breast cancer; Cholangiocarcinoma; Colorectal cancer; Glioblastoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 22 Dec 2021 This trial has been completed in Belgium., according to European Clinical Trials Database record.
- 05 Oct 2021 This trial has been completed in France., according to European Clinical Trials Database record.
- 21 Feb 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.